RV3 BB vaccine - Bio Farma/Murdoch Childrens Research Institute

Drug Profile

RV3 BB vaccine - Bio Farma/Murdoch Childrens Research Institute

Latest Information Update: 08 May 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Murdoch Childrens Research Institute
  • Developer Bio Farma Indonesia; Murdoch Childrens Research Institute
  • Class Rotavirus vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase II Rotavirus infections

Most Recent Events

  • 21 Apr 2018 Vaccine efficacy data from a phase I trial in Rotavirus infections presented at the 28th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID - 2018)
  • 09 Apr 2018 Phase-I clinical trials in Rotavirus infections (In neonates, In infants, In adolescents, In children, In adults, Prevention) in Indonesia (PO) (NCT03462108)
  • 06 Apr 2018 Murdoch Childrens Research Institute plans a phase II trial for Rotavirus infections (Prevention; In neonates; In infants) in Malawi in April 2018 (NCT03483116)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top